Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Virus|
|Published species reactivity||Virus|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Hexon antigen of human and canine adenoviruses (Type 1).|
|Storage buffer||PBS, pH 7.4|
|Contains||0.09% sodium azide|
|Storage Conditions||4°C or -20°C if preferred|
|Tested Applications||Dilution *|
|ELISA (ELISA)||Assay Dependent|
|Immunodiffusion (IDF)||Assay Dependent|
|Immunohistochemistry (Frozen) (IHC (F))||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
It is likely that this antibody will react with all mammalian Adenoviruses.
Adenoviruses are DNA viruses generally widespread in nature that are frequently the cause of acute upper respiratory tract infections (i.e. common colds). Forty-seven known serotypes have been isolated since they were first discovered in 1953 with 3 types known to cause gastroenteritis. Several types have oncogenic potential though most cause self-limiting febrile illnesses characterized by inflammation of conjunctivae and the respiratory tract. The virus can be isolated from the majority of tonsils/adenoids surgically removed, indicating latent infections. It is not known how long the virus can persist in the body, or whether it is capable of reactivation after long periods. In patients experiencing immunosuppression (e.g. AIDS) it can be reactivated causing disease.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
MA1-82982 was used in immunohistochemistry to construct a novel oncolytic adenovirus with enhanced specificity and antitumor effect in the model of murine kidney cancer
|Guse K,Diaconu I,Rajecki M,Sloniecka M,Hakkarainen T,Ristimäki A,Kanerva A,Pesonen S,Hemminki A||Gene therapy (16:1009)||2009|